Clinical Trials

We have initiated Phase 1 studies for our Treg therapy and our Teff biologic.

7101 Clinical Trial for RA

We have initiated a Phase 1 study to evaluate the safety and proof-of-mechanism of our lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis.

For more information, please see the 7101 RA study on

Learn More

7101 Clinical Trial for Hidradenitis Suppurativa

This study will test the safety and effects of SBT-77-7101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.

For more information, please see the 7101 study for hidradenitis suppurativa on

Learn More

5301 Clinical Trial

We are conducting a Phase 1 study of SBT-11-5301, our effector T cell-modulating biologic, in healthy participants.

For more information, please see the 5301 study on

Learn More